Skip to main content

Muscle Spasticity

9
Pipeline Programs
7
Companies
14
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
3
5
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

AbbVie
BOTOXApproved
onabotulinumtoxina
AbbVie
Acetylcholine Release Inhibitor [EPC]single-use1991
112M Part D
Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009
3M Part D
AbbVie
BOTOX COSMETICApproved
onabotulinumtoxina
AbbVie
Acetylcholine Release Inhibitor [EPC]single-use1991

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
7 programs
3
1
Botulinum Toxin Type A 900kDPhase 41 trial
botulinum toxin Type APhase 31 trial
onabotulinumtoxinAPhase 31 trial
onabotulinumtoxinAPhase 31 trial
No treatmentN/A1 trial
+2 more programs
Active Trials
NCT01383681Completed235Est. Oct 2012
NCT01387074Completed108Est. Jan 2013
NCT01930786Completed744Est. Oct 2017
+4 more trials
Ipsen
IpsenChina - Tianjin
1 program
1
Botulinum toxin type APHASE_41 trial
Active Trials
NCT00234546Completed162Est. Oct 2007
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Baclofen bolus injectionPhase 41 trial
Active Trials
NCT02903823Completed27Est. Feb 2019
Biocorp
BiocorpFrance - Issoire
1 program
1
MTR-601Phase 11 trial
Active Trials
NCT06117020Completed89Est. Oct 2024
PathMaker Neurosystems
2 programs
MyoRegulator®N/A1 trial
MyoRegulator® deviceN/A1 trial
Active Trials
NCT04780191Completed44Est. Jan 2021
NCT04742257Terminated28Est. Jun 2024
Motric Bio
Motric BioCA - Oakland
1 program
MTR-601PHASE_1
Teva
TevaIsrael - Petach Tikva
1 program
TizanidinePHASE_1_22 trials
Active Trials
NCT00287157Completed5Est. May 2007
NCT00358293Completed20Est. Feb 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MedtronicBaclofen bolus injection
AbbVieBotulinum Toxin Type A 900kD
IpsenBotulinum toxin type A
AbbVieonabotulinumtoxinA
AbbVieonabotulinumtoxinA
AbbViebotulinum toxin Type A
TevaTizanidine
BiocorpMTR-601
TevaTizanidine
PathMaker NeurosystemsMyoRegulator® device
PathMaker NeurosystemsMyoRegulator®
AbbVieonabotulinumtoxinA
AbbViebotulinum toxin Type A
AbbVieNo treatment

Clinical Trials (14)

Total enrollment: 2,257 patients across 14 trials

NCT02903823MedtronicBaclofen bolus injection

Intrathecal (IT) Baclofen Drug Distribution

Start: Apr 2016Est. completion: Feb 201927 patients
Phase 4Completed
NCT00549783AbbVieBotulinum Toxin Type A 900kD

BOTOX® Economic Spasticity Trial (BEST)

Start: Oct 2007Est. completion: Jul 2010274 patients
Phase 4Completed
NCT00234546IpsenBotulinum toxin type A

Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity

Start: Feb 2003Est. completion: Oct 2007162 patients
Phase 4Completed
NCT02145689AbbVieonabotulinumtoxinA

Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Start: Aug 2014Est. completion: May 20170
Phase 3Withdrawn
NCT02145676AbbVieonabotulinumtoxinA

OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity

Start: May 2014Est. completion: Dec 201553 patients
Phase 3Terminated
NCT01575054AbbViebotulinum toxin Type A

BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity

Start: May 2012Est. completion: Jul 2015468 patients
Phase 3Completed
NCT00358293TevaTizanidine

Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

Start: Dec 2006Est. completion: Feb 200720 patients
Phase 1/2Completed
NCT06117020BiocorpMTR-601

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

Start: Sep 2023Est. completion: Oct 202489 patients
Phase 1Completed
NCT00287157TevaTizanidine

Pilot, Proof-of-Concept Study of Sublingual Tizanidine in Children With Chronic Traumatic Brain Injury (TBI)

Start: Dec 2006Est. completion: May 20075 patients
Phase 1Completed
NCT04742257PathMaker NeurosystemsMyoRegulator® device

Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

Start: Mar 2022Est. completion: Jun 202428 patients
N/ATerminated
NCT04780191PathMaker NeurosystemsMyoRegulator®

Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke

Start: Jul 2018Est. completion: Jan 202144 patients
N/ACompleted
NCT01930786AbbVieonabotulinumtoxinA

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment

Start: Oct 2013Est. completion: Oct 2017744 patients
N/ACompleted
NCT01387074AbbViebotulinum toxin Type A

Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity

Start: Jun 2011Est. completion: Jan 2013108 patients
N/ACompleted
NCT01383681AbbVieNo treatment

Retrospective Study of Patients With Spasticity in the Spanish Population

Start: Feb 2011Est. completion: Oct 2012235 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.